HTS and rational drug design to generate a class of 5-HT(2C)-selective ligands for possible use in schizophrenia

ChemMedChem. 2010 Aug 2;5(8):1221-5. doi: 10.1002/cmdc.201000186.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line
  • Clinical Trials as Topic
  • Cyclopropanes / chemical synthesis
  • Cyclopropanes / chemistry*
  • Cyclopropanes / therapeutic use
  • Drug Design
  • High-Throughput Screening Assays
  • Humans
  • Ligands*
  • Methylamines / chemical synthesis
  • Methylamines / chemistry*
  • Methylamines / therapeutic use
  • Mice
  • Phencyclidine / chemical synthesis
  • Phencyclidine / chemistry
  • Phencyclidine / therapeutic use
  • Receptor, Serotonin, 5-HT2A / metabolism
  • Receptor, Serotonin, 5-HT2B / metabolism
  • Receptor, Serotonin, 5-HT2C / metabolism
  • Schizophrenia / drug therapy*
  • Serotonin 5-HT2 Receptor Agonists*
  • Serotonin 5-HT2 Receptor Antagonists
  • Stereoisomerism
  • Structure-Activity Relationship

Substances

  • Cyclopropanes
  • Ligands
  • Methylamines
  • Receptor, Serotonin, 5-HT2A
  • Receptor, Serotonin, 5-HT2B
  • Receptor, Serotonin, 5-HT2C
  • Serotonin 5-HT2 Receptor Agonists
  • Serotonin 5-HT2 Receptor Antagonists
  • Phencyclidine